Regular Follow-up of Olanzapine Blood Levels and Impaired Glucose Tolerance in Olanzapine-induced Diabetic Ketoacidosis: A Case Report

DOI 被引用文献1件 参考文献6件
  • Kinoshita Haruyuki
    Department of Cardiology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center Department of Intensive Care Medicine, National Hospital Organization Kure Medical Center and Chugoku Cancer Center
  • Miyagatani Yasusuke
    Department of Intensive Care Medicine, National Hospital Organization Kure Medical Center and Chugoku Cancer Center
  • Murao Masaki
    Department of Intensive Care Medicine, National Hospital Organization Kure Medical Center and Chugoku Cancer Center
  • Kamimura Yusuke
    Department of Intensive Care Medicine, National Hospital Organization Kure Medical Center and Chugoku Cancer Center

この論文をさがす

抄録

A 29-year-old man was admitted to our hospital with severe nausea and hyperglycemia due to diabetic ketoacidosis (DKA). He had started receiving olanzapine (2.5 mg/day) from another hospital for clinical depression 3 months before presentation. His olanzapine plasma level on the second day (before the administration of insulin) was 1.887 ng/mL. (The therapeutic blood level is 9.3 ng/ml after 24 hours in the acute phase). By checking both the plasma level of olanzapine and the U-CPR every few days, we tried to verify impaired glucose tolerance during treatment with olanzapine. Our findings suggest that even young adults who are judged to not be at any risk of diabetes can develop DKA at low plasma concentrations of olanzapine (even in low-dose olanzapine therapy), and can recover from impaired glucose tolerance. In addition, HbA1c levels go down as insulin secretory ability improves.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (6)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ